Newest Issue is Out. Get your exclusive copy today.
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Apollomics, Inc discovered novel APL-106 (uproleselan) for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) in China. AML is an aggressive disease and relapsed/refractory having an extremely poor prognosis in patients....
Tiragolumab, a novel cancer immunotherapy discovered for the treatment of metastatic Non-small Cell Lung Cancer (NSCLC). Tiragolumab, is the first anti-TIGIT molecule introduced to bind with TIGIT, a protein receptor on immune cells. It functions as an immune amplifier, by improving the body’s immune response. By combining with TIGIT...
Novartis has discovered a new Xolair® indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for adults. Xolair® (omalizumab), is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth...
Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC)....
Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences. Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma...
BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer. Plinabulin is a first-in-class differentiated immune and stem cell modulator....
Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS). Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen....
GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody...
Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor. AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment...
Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies....
